{"slug":"what-are-peptides-diabetic-neuropathy","verification":{"valid":true,"entries":2,"head":"91c8399f75df2c9faf144beb5e9f48e05b1edd5d647beeb39ac3c49ca6c12fb0"},"energy":{"passes":2,"tokens_in":25716,"tokens_out":2478,"tokens_total":28194,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"91c8399f75df2c9faf144beb5e9f48e05b1edd5d647beeb39ac3c49ca6c12fb0"},"provenance":[{"ts":"2026-06-29T22:04:46.523Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Diabetic Neuropathy\nSlug: what-are-peptides-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\"slug\":\"what-are-peptides-diabetic-neuropathy\",\"title\":\"What Are Peptides for Diabetic Neuropathy\",\"body\":\"## What's breaking down\\nDiabetic neuropathy involves progressive nerve damage tied to chronic high blood sugar. Layers include reduced blood flow to nerves (endoneurial ischemia), oxidative stress and inflammation that harm Schwann cells and axons, loss of small fiber density, and slowed nerve conduction. Over time repair pathways lag behind ongoing breakdown, leaving symptoms like pain, numbness, and impaired sensation. Peptides under study target repair signals such as improved microcirculation or innate repair receptor activation rather than only symptom suppression.\\n\\n## How these fit together\\nSingle-compound focus applies here. No multi-peptide stack data appears in the scoped evidence. Any combination would map distinct layers — for instance one peptide addressing vascular support and another neural repair — without overlap in the same pathway.\\n\\n## What the evidence actually shows\\nHuman trials exist mainly for C-peptide and ARA-290. Preclinical work covers additional peptides but remains limited to animal models.\\n\\n## What scientists say\\nResearchers note C-peptide replacement can improve aspects of nerve function in type 1 diabetes patients, though results vary by endpoint (source s5, s6). ARA-290 trials in type 2 diabetes and sarcoidosis show symptom relief and corneal nerve fiber density gains in select patients (source s27, s28). Animal studies with thymosin beta-4 report better nerve conduction and vascular density in diabetic mice (source s20).\\n\\n## What people say on Reddit\\nAnecdotal reports mention interest in BPC-157 for nerve issues but lack controlled verification and remain speculative.\\n\\n## What people say on X\\nPosts discuss emerging peptides like ARA-290 for neuropathy pain relief, citing trial summaries, yet these stay at the level of individual commentary without new data.\\n\\n## What we do not know\\nLong-term human outcomes for","tokens_in":25716,"tokens_out":2478,"cost":0,"prev":"genesis","hash":"9c3b6c64065ff52f5c0b5ef7e59f74b92c17955e2f6c015361e6cfa9eebc1336"},{"ts":"2026-07-17T02:43:31.009Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-diabetic-neuropathy","response":"16 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9c3b6c64065ff52f5c0b5ef7e59f74b92c17955e2f6c015361e6cfa9eebc1336","hash":"91c8399f75df2c9faf144beb5e9f48e05b1edd5d647beeb39ac3c49ca6c12fb0"}]}